Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 12 May 2021
PHARMAC funding 'affects all New Zealanders'
12 May 2021 - Doubling the funding for drug-buying agency PHARMAC will save lives and allow more people to live ...
Posted by Michael Wonder on 12 May 2021
Pfizer asks UK to clear vaccine for teens
12 May 2021 - Pfizer has submitted data on its COVID-19 vaccine among 12- to 15-year olds to Britain's health ...
Posted by Michael Wonder on 12 May 2021
Decision to fund tacrolimus ointment for people with facial eczema
4 May 2021 - PHARMAC is pleased to announce a decision to fund tacrolimus ointment for the treatment of facial ...
Posted by Michael Wonder on 12 May 2021
Impacts to medicine supply from India
12 May 2021 - PHARMAC is in constant contact with our suppliers as the impact of COVID-19 on India unfolds. ...
Posted by Michael Wonder on 11 May 2021
MTAA optimistic as Government rejects insurer led push to abolish Prosthesis List
11 May 2021 - The Medical Technology Association of Australia has welcomed the Government’s decision to retain the Prostheses List ...
Posted by Michael Wonder on 11 May 2021
A shot at vaccine self-reliance via BioCina and University of Adelaide partnership
11 May 2021 - Australia could achieve total COVID-19 vaccine self-reliance within six months and produce enough synthetic vaccine to ...
Posted by Michael Wonder on 11 May 2021
The pharma industry needs to measure patient experience from the patients’ perspectives
10 May 2021 - The relationship between clinical outcomes and the patient experience — the sum of all of interactions ...
Posted by Michael Wonder on 11 May 2021
International IP protection at risk for COVID-19 vaccines
11 May 2021 - The global biotech industry is united in its drive for equitable access to COVID-19 vaccines, but ...
Posted by Michael Wonder on 11 May 2021
CMS expanding efforts to grow COVID-19 vaccine confidence and uptake amongst nation’s most vulnerable
11 May 2021 - CMS builds on whole of Government COVID-19 response with vaccination education, offering and reporting. ...
Posted by Michael Wonder on 11 May 2021
Alberta faces shortage of COVID-19 drug as global demand spikes
11 May 2021 - Provinces with highest case rates hit by shortage of medication for sickest patients. ...
Posted by Michael Wonder on 11 May 2021
Budget 2021–22: generational change and record investment in the health of Australians
11 May 2021 - A joint media release outlining the Morrison Government's $121.4 billion in 2021–22 and $503 billion investment into ...
Posted by Michael Wonder on 11 May 2021
ICER publishes final evidence report and policy recommendations on therapies for multiple myeloma
11 May 2021 - Independent appraisal committee unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel ...
Posted by Michael Wonder on 11 May 2021
Expensive migraine drug Emgality added to PBS
11 May 2021 - An expensive migraine drug will be listed on the Pharmaceuticals Benefits Scheme, making it affordable for ...
Posted by Michael Wonder on 11 May 2021
Health front and centre of economic recovery
11 May 2021 - Treasurer Josh Frydenberg places the nation’s health, wellbeing and recovery from COVID-19 front and centre of ...
Posted by Michael Wonder on 11 May 2021
FDA grants fast track designation to CERC-002 for treatment of hospitalised patients with COVID-19
11 May 2021 - Cerecor today announced that the U.S. FDA has granted fast track designation to CERC-002 for treatment of ...